ReviewMolecular oncology2014
Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe.
Review in Molecular oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Whole-Genome Sequencing as Tool for Investigating International Tuberculosis Outbreaks: A Systematic Review.Frontiers in public health · 2019Pooled it
- When genomics and histopathology diverge: insights from pathologic review of genomic-directed specimens.Virchows Archiv : an international journal of pathology · 2026Article
- Review
- Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.Journal of neuro-oncology · 2024Review
- Learning mechanisms and outcomes of an interprofessional molecular pathology workshop for residents.Academic pathology · 2022Article
- Article
- Primary sellar melanocytoma: pathological, clinical and treatment review.Journal of endocrinological investigation · 2020Review
- The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology.Virchows Archiv : an international journal of pathology · 2020Review
- Article
- Pharmacogenetic and pharmacogenomic discovery strategies.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer.Oncotarget · 2018Article
- Strategies for identification of somatic variants using the Ion Torrent deep targeted sequencing platform.BMC bioinformatics · 2018Article
- Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey.Virchows Archiv : an international journal of pathology · 2017Article
- Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.PLoS medicine · 2017Article
- The Role of ATRX in Glioma Biology.Frontiers in oncology · 2017Review
- Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy.PloS one · 2017Article
- RAS testing in metastatic colorectal cancer: advances in Europe.Virchows Archiv : an international journal of pathology · 2016Review
- Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.Journal of the National Cancer Institute · 2016Review
- Quality assurance in clinical trials--the role of pathology.Virchows Archiv : an international journal of pathology · 2016Review
- Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers.Virchows Archiv : an international journal of pathology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor evaluation in pathology is more and more based on a combination of traditional histopathology and molecular analysis. Due to the rapid development of new cancer treatments that specifically target aberrant proteins present in tumor cells, treatment decisions are increasingly based on the molecular features of the tumor. Not only the number of patients eligible for targeted precision medicine, but also the number of molecular targets per patient and tumor type is rising. Diagnostic molecular pathology, the discipline that determines the molecular aberrations present in tumors for diagnostic, prognostic or predictive purposes, is faced with true challenges. The laboratories have to meet the need of comprehensive molecular testing using only limited amount of tumor tissue, mostly fixed in formalin and embedded in paraffin (FFPE), in short turnaround time. Choices must be made for analytical methods that provide accurate, reliable and cost-effective results. Validation of the test procedures and results is essential. In addition, participation and good performance in internal (IQA) and external quality assurance (EQA) schemes is mandatory. In this review, we critically evaluate the validation procedure for comprehensive molecular tests as well as the organization of quality assurance and assessment of competence of diagnostic molecular pathology laboratories within Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.